Business
Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York
NEWARK, Calif., Feb. 19, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, Calif., Feb. 19, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annual Global Healthcare Conference in New York.\nPresentation details:Event: SVB Leerink 9th Annual Global Healthcare ConferenceDate: Tuesday, Feb. 25Time: 10:30 a.m. EST\nA live and archived audio webcast of the presentation can be accessed by visiting the Investors page of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.\nAbout Protagonist Therapeutics, Inc.\nProtagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload anemia and related rare blood diseases including beta-thalassemia, polycythemia vera and hereditary hemochromatosis. PTG-200 is an oral, gut-restricted interleukin-23 receptor specific antagonist peptide in Phase 2 clinical development for the potential treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the potential treatment of inflammatory bowel disease, with a Phase 2 ulcerative colitis study expected to commence in the second quarter of 2020.\nProtagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com. \nCautionary Note on Forward-Looking Statements\nThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential of PN-943 as a possible treatment of inflammatory bowel disease, the potential of improved safety and tolerability for PN-943 compared to antibody therapeutics a...